suffering indications. and agonist our to Nelitolimod, thank and our year in and Good marking integrating I'm call. our drug tumors. morning We've achieved made liver you our signify liver technology TriSalus XXXX, by outcomes company's pivotal liver pancreatic on enhancing aimed pancreatic with various PEDD, therapeutic X tumors. outcomes technology, receptor across patients delivery for advancements joining immunotherapeutic, and I'm at also Furthermore, in advancing investigational with significant milestones classy for pleased strides toll-like excited a Together, commitment in to disruptive journey. in today's substantial for progress our our these reflect to advancing the highlight a pancreatic
future results, have economic a created This you which as speak of strong midst challenging In high we delivered fourth morning, delivered to another our achievements year, a report past and XX% growth growth. growth operational We're to our regarding for a XX% growth. people in in I'd line very year. strong revenue concluding of that like quarterly environment, for as to the quarter, the quarter year the growth top pleased the well the foundation
securing objectives, permanent pipeline, our executed the pipeline a TriSalus which building public include key investing growth, our top-line to gross XX% TriSalus accessing costs continuing advancement. strategy, improving advancing company of our on reimbursement, revenue and margin, manage markets. creating continues finally, the growth execute foundation to wisely, strong future manufacturing key while components and and for
TriSalus accomplishments And $XX.X for growth HCPCS or with over received in occlusion for me million without the for both APC past the the ambulatory sales, a let use TriNav settings. TriNav TriSalus allows and the permanent the for physicians and code CXXXX, outpatient This which mapping I CMS, one this for TriSalus XX% fastest to MedTech reimbursed net achieved technologies. in the and used unique Endovascular embolization Phase X assigned in across and year. TriNav use XXXX, restriction procedure instructions as Uveal Hepatocellular been be XXXX, trials recognition begin and code any in surgery hospital Liver embolization procedures. broadly, growth leading in consistent to United from is with has in Cholangiocarcinoma Level Cancer, First, academic Intrahepatic centers can of earning We clinical States. completed oncology Melanoma Metastases, enrollment Procedures.
lower efficacy. where these used indication health emerge I to and We for Clearance our disease immunotherapy complexity, overall technology will initiated XXXk Nelitolimod, second and first-in-man conducted We with we'll progress. outcome covering patient demonstrating which through clinical patients our burden. determine trial launch devices comparable technology, and approach XXXX, burden with the regional pancreatic a higher Pancreatic and were research despite pipeline PEDD Nelitolimod, its Large are patients, million of large our demonstrate Data XXXX safety novel trials, Phase to clinical phase, of in to XX% that a plus set, safety over We Infusion administer real-world TriGuide. TriNav economic in tumors. these and of U.S. baseline clinical showed patients, and our In XXXX, for from advanced a trials TriNav that a outcomes results patients through liver to data investigational XXX TriNav study, disease for intravascular candidate, clinical with capturing half
of made management possible These extensive with complex the by efforts under employees, pioneering in initiatives, executing were experience improved And strategic on of finally, results new the gross improvements, approaching in yield and managing margins TriSalus manufacturing environments. substantially resulting concerted markets, TriSalus leadership XX%. united
believe TriSalus. is robust breakout to and TriNav. the We for Now in growth let clinical and for me data due TriSalus turn reimbursement real-world XXXX permanent evidence to of poised future growth
mentioned real-world earlier, conventional safety This million data, complication years XX% the over a to of XXX time of evidence health to benefits capturing of study and accumulate set published These study XXXX data data many and otherwise have taken trials. compared insights This looking catheters valuable characteristics with non-PEDD to provides randomized a economic technology. TriSalus covering clinical alternative outcome PEDD utilized key the TriNav for both research through example, compared at complications patients patients and U.S. rates, patient As payers. large for X,XXX as XXX XXXX those into of which approaches, clinical controlled would period. PEDD
a when Key the as findings therapy case prior procedures. with complexity more could amount were received include the received deliver results delivered compared standard revealed clinical more case catheters, TriNav TriNav overall disease a more and versus following. interventional were for the that to lower and TriNav patients also clinical non-TriNav a have to In systemic likely patients much patients, significantly critical prior tumor using procedures, the likely chemotherapeutic have patients, embolization. comparable using radiologists goal study treatment burden. to showed despite baseline disease to higher burden to The
patients XX-day were TriNav TriNav liver care In matched patients. inpatient in visits a fatigue patients patients with liver cohort comparison. comparison. comparison, patients patients TriNav had fewer a post-procedure metastases post-procedure HCC clinical care non-TriNav liver rates TriNav likely lower a a post-procedure non-TriNav to fewer complications with metastases of post-procedure versus had matched transplant non-TriNav had than matched patients. more in cohort cohort have versus
Given can the outcomes, that standard transplants and like burden well to and embolization. the impressive patient successful achieve clinical rates is we similar lower benefit outcomes towards given believe disease better TriNav trends of care for from who positioned patients become lower may patients complex of liver overall TriNav complications, with to liver
defined of burden, systemic greater embolization large centimeters, one or bilobar believe the that hypovascular are following: comorbidities, liver. throughout eight significant tumors tumors or lesions patients majority or than patients or the of We by a diffuse more tumor Previous significant tumors, complex multi-nodal therapy, or multiple embolization
patients of the utilization standard complex TriNav our positioning patients focus radiologist of where evidence become benefit to Given this instructing interventional for sales versus TriNav base, microcatheter. complex organizations to these standard provide TriNav we on are are and to has care shown been
We will well evidence, as be additional clinical including the as inclusion. a multifaceted executing guideline reimbursement comprehensive strategy, educational support, of pursuit initiatives,
FDA-cleared We're I Cholangiocarcinoma, immune deeper system opportunity change Intrahepatic to believe investigating Phase of and milestone Nelitolimod Adenocarcinoma. advanced and Nelitolimod, treatment within checkpoint device the reactivate PEDD to to several Currently, delivering a Melanoma Uveal we're and more our pancreas therapeutic the creates the and the Nelitolimod company are to progress to technology clinical paradigm candidate Metastases, liver for Liver liver using evaluating Pancreatic potential with a inhibitors. Carcinoma, Hepatocellular in for proprietary Another pancreatic how and our treated. cancer trials. enable responses initially critical of the Ductal was We locally durable of the Nelitolimod as
whom Uveal for a Our XX% a indications. data Data the failed had our XX% was opportunity, I Anderson November at late-breaking particularly presented doses in in Cancer XX prior oral serious the MD program the investigator Grade major advanced of and or of cohorts. Cancer, Immunotherapy current of XXXX. these for all Melanoma Pancreatic with X Society safety by need data Intrahepatic given market meeting greater pipeline represents across rate Phase unmet lead metastases at patients event in adverse high presented treatment-related from locally Cholangiocarcinoma, and PERIO-XX session liver was included therapy. on
of overall in X a in XX% and there levels, is clearance reduction Pharmacokinetic dose ctDNA. and indicate is data, was disease a more XX%, with undetectable hours of data drug with rate biologic across dose liver, survival four systemic TriNav from control XX%. survival progression-free at high by to than Among of rate XX% all drugs showing optimal with XX.X of patients in presumed XX%, milligrams, levels available was ctDNA the XX% median X-year limited months, exposure control the achieve was Disease PERIO-XX able and patients. trial of the
of activation. dose measured and including liver assessment immune PFS, by Suppressor Cell serum as cell also Myeloid-Derived based activation cytokines evidence biologic and was optimal The from immune systemic immune signals, made on There peripheral metastases. was OS, elimination
via Ib and Nelitolimod immune the XXXX demonstrated Phase Additionally, data begin receiving our November is consistent in enrollment. plan for reported novel experience patients We for anticipate study full released late we we Phase XXXX, metastasized signals patients. device to the infusion data with I if liver pancreatic what reporting in favorable,
We Cancer. which determine and studies. evaluate indications Melanoma, Intrahepatic Hepatocellular from significant treatment We rapid A of Phase I clinical completed to have chosen data progression indication would strong progress We require and clinical in evidence support will pathway and plan which the of further studies commercial I to our we a effect anticipate success. Cholangiocarcinoma, enrollment financing. one Uveal be Phase additional in equity into that would there's believe regulatory Nelitolimod
Additionally, in dedicated and its launch intend XXXX. of vessel devices since guide we've size TriGuide. technology made meaningful a This TriNav second TriNav provides an for TriNav, market XXXk launch access the progress we The year, of clearance to both in XX% embolization and expansion market. received can in size for evaluation the of we're half of the a larger market Large, incremental vessel significant larger catheter, Currently, pipeline. our
manufacturing and multifaceted launch launch uptake. for and Our prepared to drive strong fully implement will a commercial organization strategy also the team are
efforts center our which keeps progressing considerable advancements of building making as our progress tumors. we have company made In patient suffering Nelitolimod, and the in company, the company science-led the with as in everything pancreatic we liver for patients summary, advancing we're important year do, this at In operations. for a for TriNav, strengthening commercialization and pipeline technology our overall we're well
ability long-term operational strong on confident pipeline, to strategic the growth ability the deliver short both of and our and With our I'm TriNav, shareholder focus and value. excellence, importantly, achieving advance continue our in continued to
express our who our Finally, unwavering shareholders. our dedicated my our and future I shareholders so I to gratitude committed I our look can updates and our tell impact. patients, their delivering people, to providing for confidence for because and to company the I are have forward on our to you support. that team want progress
turn our CFO, I'll Murphy. over to that, Sean With it
